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Consent for children participating in 
research
To the Editor: With reference to the article and more recent letter 
on the implications for researchers, service providers and policy 
makers of child consent in South African law,1,2 I wish to put forward 
a different but more appropriate approach to consent for children 
participating in research. Although I agree that s71 of the National 
Health Act of 20033 is not in force, the Guidelines of the National 
Health Research Ethics Committee are.4 The NHREC is quite clear 
when it comes to consent for children participating in research. 
Research should be of minimal risk and consent for minors must 
be obtained from the parents or legal guardian in all but exceptional 
circumstances (such as emergencies), as well from as the minor 
where s/he is competent to make the decision. This is consistent 
with international practice, and I urge all researchers and Human 
Research Ethics Committees to be compliant with this guideline in 
the meantime.
Shan Naidoo
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Slack, Strode and Essack reply: Professor Naidoo argues that an 
‘appropriate approach’ to child research is that the ‘research should 
be of minimal risk and consent for minors must be obtained from 
the parent or legal guardian in all but exceptional instances’ and, 
moreover, that this is consistent with South African national ethical 
guidelines and international practice. 
On the contrary, it is not clear why this proposal is appropriate in 
all instances, and our South African ethical-legal framework does not 
provide unqualified support for such a position. 
Current South African ethical guidelines, including the Good 
Practice guidelines1 and the general ethical guidelines Structures, 
Principles and Processes,2 provide that in certain circumstances 
children are permitted to be enrolled in research that presents more 
than minimal risk. Where the research procedures hold out the 
prospect of direct benefit, there is no express cap on the risk level, 
although the risks must be reasonable in relation to the anticipated 
benefit (and appropriately minimised); and where the research 
procedures do not hold out the prospect of direct benefit, the risks 
must represent a minor increase over minimal risk.3 This position 
is echoed in international frameworks, such as the Code of Federal 
Regulations in the USA.4 Should children’s participation in research 
be limited exclusively to minimal-risk research, it is difficult to see 
how children would ever be enrolled in clinical trials of experimental 
products. 
Furthermore, in current South African ethical guidelines child 
participation in research is sometimes permissible even when 
parental or guardianship consent is not obtained, for example 
Structures, Principles and Processes2 (correctly) allow older adolescents 
to participate in minimal-risk research with independent consent. 
The Good Practice guidelines1 also recognise the ability of caregivers 
providing long-term day-to-day care of children to provide proxy 
consent in some instances. International frameworks also allow for 
waivers of parental consent in certain specific instances, and where 
sufficient safeguards are in place.
We do not dispute that in all instances of child research, research 
ethics committees must make complex determinations about whether 
the research presents acceptable risks to child participants; nor that 
in many instances of child research, proxy consent by an adult is 
most desirable and that in many instances proxy consent should be 
obtained from a parent/legal guardian.5 However, we argue here that 
the situation is not as simple as the proposal set out by Professor 
Naidoo, and that any competent ethico-legal framework should be 
able to accommodate a broad range of health research proposals 
involving children.  
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Mini-slings – concern regarding 
marketing of these devices in South 
Africa
To the Editor: Aggressive  marketing of medical devices impacts on 
the day-to-day practice of clinicians. The marketing of the mini-sling 
devices for stress urinary incontinence (SUI) in women is an area of 
major concern to us. SUI is the involuntary leakage of urine from the 
urethra with exertion, or on sneezing or coughing, and affects up to 
35% of women.1 It is a distressing condition and significantly impacts 
on quality of life. 
Traditional interventions include pelvic floor exercises and open 
retropubic colposuspension. Ulmsten in 1995 introduced an effective 
minimally invasive option for surgically managing SUI, the ‘tension-
free vaginal tape’ (TVT) (Gynecare, Ethicon, Somerville, USA).2 This 
was followed by development of the transoburator-type sling, which 
avoided the risks of bladder, bowel and major vascular injury.3 Both 
slings are made of synthetic mesh and are placed mid-urethrally, and 
their placement is the most commonly performed surgical procedure 
for SUI.
Long-term follow-up of Ulmsten’s original series found an 
objective cure rate of 90% at 10 years. Level 1 evidence found efficacy 
to be equivalent to that of colposuspension. Meta-analysis has further 
shown equivalence in terms of cure between the trans-obturator and 
retropubic placement of mid-urethral slings.4 
Mid-urethral slings therefore offer a highly efficacious minimally 
invasive surgical option with low postoperative morbidity. Device 
manufacturers have in the past 5 years introduced and strongly 
promoted eight further so-called ‘mini-slings’ that are claimed to be 
less invasive, and are placed via a small single vaginal incision.
There is little quality evidence to support the use of mini-slings. 
Nearly all the available studies show inferior efficacy. The most studied 
device, the TVT-Secure, was the subject of a 12-month outcome study 
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that reported an objective cure rate of 76%, considerably lower than 
the 90% reported long-term cure rate for the standard TVT.5 The 
other widely marketed device, the Mini-Arc, also has inconsistent 
outcomes with some studies showing cure rates as low as 62%.6 
Gynaecologists and urologists need to be aware of these poorer 
outcomes, for the TVT-Secur and  the Mini-Arc in particular. While 
mini-slings hold future promise, present products are inferior to 
standard sling operations and their use should be discouraged.
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Management guidelines for common 
kidney disorders relevant to South 
Africa
To the Editor: World Kidney Day (WKD), an annual event, is 
celebrated on 8 March 2012. As a project for WKD, the National 
Kidney Foundation of South Africa (NKFSA) has arranged for a 
group of experienced senior nephrologists from around the country 
to contribute to a guideline booklet presenting the diagnosis and 
state-of-the-art management of renal disorders. Its main aim is 
to educate and update general practitioners, but it should also be 
useful for under- and postgraduate students, urologists and specialist 
physicians.
The guideline is being edited and will be sent to the South African 
Renal Society for their endorsement. We aim to publish the guideline 
as a supplement to the South African Medical Journal. We thank 
the contributors to and supporters of the project, and the National 
Lotteries Distribution Trust Fund for financial support towards the 
initial draft copy of the guideline. 
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Chairman, National Kidney Foundation of South Africa
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Health professionals should be 
speaking out about the victimisation 
of doctors in Bahrain
To the Editor: Doctors in Bahrain who treated people wounded 
during and after demonstrations have been arrested, tried by a 
military court and given sentences of up to 15 years’ imprisonment. 
A report by the Physicians for Human Rights1 recounts the result 
of an on-the-spot inquiry as follows: ‘Our investigators spoke to 
eyewitnesses of abducted physicians, some of whom were ripped 
from their homes in the middle of the night by masked security 
forces ... [the report] documents other violations of medical 
neutrality, including the beating, abuse and threatening of Shi’a 
physicians at Salmaniya Hospital; government security forces stealing 
ambulances and posing as medics; the militarisation of hospitals 
and clinics, thus obstructing medical care; and rampant fear that 
prevents patients from seeking urgent medical treatment.’ Most of the 
doctors are women, and there have been reports of torture, including 
electrocution and threats of rape while in detention.2
These accounts are shocking and remind South Africans of a sorry 
history where human rights abuses at the hands of security forces 
were allowed to go unchecked and where the health sector was drawn 
willingly and unwillingly into violations of the rights of patients and 
professionals.3 Not surprisingly, there has been sustained outcry from 
the medical profession in other parts of the world.4-7 Following the 
exposé by Physicians for Human Rights, and pressure by the World 
Health Organization and the World Medical Association, it was 
announced by a civilian court that some charges against 20 health 
professionals would be dropped and that a new trial would begin to 
assess the allegations.8  
We ask why there has been so little outcry in South Africa, 
a country whose history should make it acutely aware of the 
consequences of the political abuse of doctors. The South African 
Medical Association released a Medigram reporting the resolution 
of the WMA,9 but has not taken any proactive steps to champion 
the cause of the persecuted doctors. Why has SAMA not been more 
active? Why have members of the medical profession not seen it as 
their ethical obligation to take action in solidarity with colleagues, if 
only to press our government, a member of the UN Security Council, 
to take diplomatic action? One of the consistent findings of research 
into complicity of health professionals in human rights abuses3,10,11 
has been the effect of isolation and a failure to stand up for colleagues 
under threat, a finding echoed in the conclusions of the Truth and 
Reconciliation Commission.3,11 
It appears that since the late 1970s we have not learnt sufficiently 
the importance of health professionals speaking truth to power. One 
of us (SS) wrote to the President of SAMA, urging SAMA to take 
action, to which there was not even an acknowledgement. South 
Africans deserve better.
Stuart Saunders
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University of Cape Town
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Side-effect of acetazolamide in 
prevention of acute mountain sickness
To the Editor: The scientific letter by Firth et al.1 about the side-
effect of acetazolamide on a hiker on Mt Kilimanjaro makes a 
rather hasty conclusion about the recommendation of acetazolamide 
to prevent acute mountain sickness (AMS), especially in a rapid 
ascent climb such as Kilimanjaro. It is difficult to disagree about 
the pathophysiology of acetazolamide causing corneal oedema, but 
we must note that it is a drug used for glaucoma treatment,2 and 
the dosage regimen is usually higher than that prescribed for the 
prevention of AMS. Interestingly, the authors did not mention the 
dose and duration of acetazolamide in the article. The cause-effect 
relationship is difficult to establish from this case report without 
knowing the dosage regimen and control. Based on the rare side-
effect (if indeed it is) in this report, it would not be justifiable to 
advise against using acetazolamide as a prophylactic of AMS; this 
could rather invite other serious acute altitude illnesses that would be 
far more probable were it not used. Major trials with large numbers 
of participants have reported a fairly safe outcome of acetazolamide.3 
Hence, we should continue using acetazolamide with caution for 
preventing AMS where there is rapid ascent profile.
Matiram Pun
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Firth, Gray and Novis reply: We thank Dr Pun for his comments. 
The climber did not remember the dose she took, but thinks it was 
250 mg daily by mouth, starting on the ascent. While painful drug-
induced myopia with low doses of sulphonamides is a rare but well-
described complication, this appears to involve different mechanisms 
to impairment of corneal endothelial function.1 Although we 
pointed out that a causal pathophysiology was not demonstrated,2 
we therefore speculate that the interaction of drug effect with rapid 
ascent played a role.
Irrespective of the pathophysiology, it is prudent to discontinue a 
drug if adverse side-effects occur after dosing. Similarly, if symptoms 
occur following rapid ascent, it is sensible to remove the possible 
cause by rapid descent. The onset of visual disturbances should 
therefore prompt discontinuation of the possibly offending drug and 
to consider descending.
Although the effectiveness of acetazolamide in preventing 
AMS during the very rapid ascent profiles typical on Kilimanjaro 
is debatable,3 we do not suggest that the prophylactic use of 
acetazolamide during gradual ascents be abandoned on the basis 
of this report; rather, the possible causes of a problem should be 
identified and removed if symptoms occur.
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